U.S. federal health agencies will formally call for an immediate pause in use of Johnson & Johnson’s single-dose COVID-19 vaccine on Tuesday after six U.S. recipients developed a rare disorder involving blood clots.
The U.S. Food and Drug Administration and the U.S. Centers for Disease Control and Prevention said in a Twitter thread that the pause has been recommended “out of an abundance of caution”
Read more:
Johnson & Johnson vaccine under review in Europe after blood clot reports
The New York Times was first to report the suspension, citing officials briefed on the decision.
“Right now, these adverse events appear to be extremely rare,” the FDA wrote on Twitter. “Treatment of this specific type of blood clot is different from the treatment that might typically be administered.”
Today FDA and @CDCgov issued a statement regarding the Johnson & Johnson #COVID19 vaccine. We are recommending a pause in the use of this vaccine out of an abundance of caution.
— U.S. FDA (@US_FDA) April 13, 2021
All the six recipients were women between the ages of 18 and 48. One woman died and a second woman in Nebraska has been hospitalized in critical condition, the NYT reported.
The CDC will convene a meeting of the Advisory Committee on Immunization Practices (ACIP) on Wednesday to further review these cases and assess their potential significance. The FDA will then review that analysis as it also investigates these cases, it said in a statement.
Read more:
Johnson & Johnson says batch of COVID-19 vaccines failed quality check
A press conference will be held at 10 a.m. EDT where officials will provide further detail on the pause.
The company’s shares were down 3 per cent before the opening bell.
The move from the U.S. regulators comes less than a week after Europe’s drug regulator said it was reviewing rare blood clots in four people in the United States who received the shot.
Canada has also approved the one-shot Johnson and Johnson vaccine, however, deliveries to the country are not expected to begin until the end of April.
Canada also moved to change recommendations for use of the AstraZeneca vaccine after the reports of very rare blood clots in some recipients, although there have been no such reports in the country.
— with Global News files
